Table 2.

Results of the Kaplan–Meier analysis of progression free and overall survival

	PFS, months (95% CI)	p value	OS, months (95% CI)	p value
Age
<64 years	10.3 (8.4–12.2)	0.714	31.9 (11.7–52.1)	0.751
≥64 years	10.4 (6.7–14.1)		27.1 (5.3–48.8)
Sex
Male	10.6 (7.5–13.6)	0.245	31.9 (12.2–51.6)	0.936
Female	10.1 (5.8–14.2)		25.8 (8.2–43.4)
ECOG PS
0–1	15.1 (9.2–20.9)	0.001	63.5 (30.8–96.2)	0.001
≥2	8.2 (3.4–12.9)		15.1 (10.7–19.5)
Disease free interval
<1 year	9.2 (5.1–13.3)	0.063	22.0 (0–50.5)	0.131
≥1 year	13.2 (9.2–17.2)		41.1 (16.1–65.9)
Lung metastasis
Yes	6.9 (2.0–11.7)	0.139	27.1 (18.4–35.7)	0.722
No	13.2 (6.7–19.7)		37.2 (12.7–61.7)
Liver metastasis
Yes	4.3 (0.0–11.1)	0.680	14.4 (0–49.1)	0.388
No	10.4 (8.9–12.0)		31.9 (15.8–48.0)
Lymph node metastasis
Yes	10.3 (7.6–13.0)	0.180	14.4 (9.1–19.7)	0.037
No	10.4 (7.9–12.9)		40.3 (28.4–52.1)
Bone metastasis
Yes	10.1 (6.6–13.4)	0.309	18.2 (13.3–23.1)	0.021
No	10.6 (8.8–12.3)		40.3 (20.2–60.3)
Brain metastasis
Yes	3.2 (2.1–4.3)	0.001	5.9 (0.1–11.7)	0.012
No	10.6 (9.0–12.1)		37.2 (17.1–57.3)
Metastasis at other site
Yes	9.1 (5.8–12.5)	0.620	27.1 (10.7–43.4)	0.384
No	10.4 (8.4–12.4)		63.5 (6.2–120.8)
Number of metastatic site
1	13.2 (8.7–17.7)	0.001	40.3 (24.7–55.8)	0.007
≥2	5.0 (0.4–9.6)		13.7 (9.3–18.1)
Previous nephrectomy
Yes	10.5 (6.0–15.1)	0.522	37.2 (19.1–55.3)	0.113
No	10.3 (7.1–13.5)		18.2 (6.6–29.7)
TKI regimen
Sunitinib	10.1 (7.6–12.5)	0.664	37.2 (15.9–58.5)	0.786
Pazopanib	10.6 (10.1–11.1)		25.8 (10.2–41.3)
Neutrophil–lymphocyte ratio
≤3.6	16.3 (10.4–22.2)	0.001	63.5 (37.4–89.6)	0.001
>3.6	5.0 (0.7–9.3)		17.0 (12.4–21.6)
Platelet–lymphocyte ratio
≤150	18.1 (6.2–29.9)	0.001	50.5 (28.5–72.4)	0.001
>150	4.4 (3.5–5.3)		13.7 (7.8–19.6)
Hemoglobin
<12 (g/dL)	7.2 (0.3–13.9)	0.237	25.8 (8.3–43.2)	0.252
≥12 (g/dL)	11.7 (8.6–14.8)		37.2 (17.5–56.8)
Corrected calcium
<10 (mg/dL)	10.3 (8.7–11.9)	0.652	31.9 (14.4–49.4)	0.206
≥10 (mg/dL)	Not reached		Not reached